Clinical Trial

Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their Caregivers

Study acronym: MMYLIFE
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 29, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Individuals with multiple myeloma (MM) are vulnerable because of the effects of systemic organ damage and the side effects of treatment. A decline in patients' health-related quality of life (HRQoL) and a compromised participation in everyday life was reported. The diagnosis of MM negatively affects the principal informal caregiver. This is a concurrent exploratory mixed methods study that involves the use of a quantitative and a qualitative approach. For the quantitative study, aims are to describe any possible relation between the identified factors with HRQoL and participation in individuals with MM and with reactions to caring and self-efficacy of caregivers. For the qualitative study, aims are to investigate "how" and "why" the disease impacts the daily life of individuals with MM and their caregivers. The final analyses will be based on the comparison of the results of the quantitative phase and the results of the qualitative phase.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-03.
Status change: Not Yet Recruiting → Recruiting 2025-08-28
Trial Details
NCT Number NCT07014865
Lead Sponsor Azienda USL Reggio Emilia - IRCCS
Conditions Multiple Myeloma (MM), Hematologic Neoplasm
Enrollment 190 participants
Start Date 2025-06-17
Primary Completion 2026-06 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-29